Pantazopoulos Dimitrios, Gouveri Evanthia, Papi Massimo, Papazoglou Dimitrios, Papanas Nikolaos
Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, 68100, Alexandroupolis, Greece.
National Institute for Health, Migration and Poverty (NIHMP), ADOI National Study Group Vulnology and Vascular Dermatology, Rome, Italy.
Adv Ther. 2025 Jun 5. doi: 10.1007/s12325-025-03257-w.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is) are well-established agents for type 2 diabetes mellitus (T2DM) management. Ongoing research has provided data on their both beneficial and adverse effects on the skin. For instance, GLP-1RAs have exhibited therapeutic benefits in psoriasis, while DPP-4is may reduce the risk of melanoma. Moreover, both of these agents may play a pivotal role in improving wound healing. However, untoward effects, such as bullous pemphigoid, highlight the need for patient monitoring. This review summarises the beneficial and adverse effects of GLP-1RAs and DPP-4is in dermatological conditions and in systemic diseases with cutaneous manifestations.
胰高血糖素样肽-1受体激动剂（GLP-1RAs）和二肽基肽酶-4抑制剂（DPP-4is）是用于管理2型糖尿病（T2DM）的成熟药物。正在进行的研究提供了关于它们对皮肤的有益和不良影响的数据。例如，GLP-1RAs在银屑病中显示出治疗益处，而DPP-4is可能降低黑色素瘤的风险。此外，这两种药物在促进伤口愈合方面可能都起着关键作用。然而，诸如大疱性类天疱疮等不良反应凸显了对患者进行监测的必要性。本综述总结了GLP-1RAs和DPP-4is在皮肤病以及有皮肤表现的全身性疾病中的有益和不良影响。
